Insider Buying: Aardvark Therapeutics (NASDAQ:AARD) CFO Buys 3,000 Shares of Stock

Aardvark Therapeutics, Inc. (NASDAQ:AARD) CFO Nelson Sun purchased 3,000 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The stock was acquired at an average cost of $14.40 per share, with a total value of $43,200.00. Following the transaction, the chief financial officer directly owned 108,484 shares of the company’s stock, valued at approximately $1,562,169.60. This represents a 2.84% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Aardvark Therapeutics Stock Performance

Aardvark Therapeutics stock traded down $1.18 during midday trading on Friday, reaching $14.43. The stock had a trading volume of 267,186 shares, compared to its average volume of 207,122. The stock has a market capitalization of $314.14 million and a P/E ratio of -6.81. The firm’s fifty day simple moving average is $11.93 and its 200-day simple moving average is $11.70. Aardvark Therapeutics, Inc. has a 1-year low of $4.88 and a 1-year high of $19.58.

Aardvark Therapeutics (NASDAQ:AARD) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.07.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on AARD shares. William Blair began coverage on Aardvark Therapeutics in a report on Friday. They issued an “outperform” rating for the company. Stifel Nicolaus assumed coverage on Aardvark Therapeutics in a research note on Monday, September 29th. They issued a “buy” rating and a $24.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aardvark Therapeutics in a report on Monday. Raymond James Financial assumed coverage on Aardvark Therapeutics in a report on Tuesday, December 2nd. They issued a “strong-buy” rating and a $47.00 target price on the stock. Finally, Royal Bank Of Canada lowered their target price on shares of Aardvark Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday, November 14th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $32.44.

Institutional Trading of Aardvark Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. UBS Group AG lifted its holdings in Aardvark Therapeutics by 5.4% during the 3rd quarter. UBS Group AG now owns 54,728 shares of the company’s stock worth $727,000 after buying an additional 2,804 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Aardvark Therapeutics in the second quarter valued at about $42,000. Bank of America Corp DE lifted its holdings in Aardvark Therapeutics by 72.9% in the second quarter. Bank of America Corp DE now owns 7,989 shares of the company’s stock valued at $108,000 after acquiring an additional 3,369 shares during the period. New York State Common Retirement Fund acquired a new stake in Aardvark Therapeutics in the second quarter valued at $99,000. Finally, Walleye Capital LLC purchased a new stake in Aardvark Therapeutics in the 1st quarter valued at approximately $88,000.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.